JP2006316058A5 - - Google Patents

Download PDF

Info

Publication number
JP2006316058A5
JP2006316058A5 JP2006132110A JP2006132110A JP2006316058A5 JP 2006316058 A5 JP2006316058 A5 JP 2006316058A5 JP 2006132110 A JP2006132110 A JP 2006132110A JP 2006132110 A JP2006132110 A JP 2006132110A JP 2006316058 A5 JP2006316058 A5 JP 2006316058A5
Authority
JP
Japan
Prior art keywords
ethoxyethyl
ethyl
pyrazolo
methylamino
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006132110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006316058A (ja
JP4271695B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006316058A publication Critical patent/JP2006316058A/ja
Publication of JP2006316058A5 publication Critical patent/JP2006316058A5/ja
Application granted granted Critical
Publication of JP4271695B2 publication Critical patent/JP4271695B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006132110A 2005-05-12 2006-05-11 無水結晶形態のN−[1−(2−エトキシエチル)−5−(N−エチル−N−メチルアミノ)−7−(4−メチルピリジン−2−イル−アミノ)−1H−ピラゾロ[4,3−d]ピリミジン−3−カルボニル]メタンスルホンアミド Expired - Fee Related JP4271695B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68044505P 2005-05-12 2005-05-12
US68171105P 2005-05-17 2005-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009001627A Division JP4996631B2 (ja) 2005-05-12 2009-01-07 無水結晶形態のN−[1−(2−エトキシエチル)−5−(N−エチル−N−メチルアミノ)−7−(4−メチルピリジン−2−イル−アミノ)−1H−ピラゾロ[4,3−d]ピリミジン−3−カルボニル]メタンスルホンアミド

Publications (3)

Publication Number Publication Date
JP2006316058A JP2006316058A (ja) 2006-11-24
JP2006316058A5 true JP2006316058A5 (https=) 2008-12-11
JP4271695B2 JP4271695B2 (ja) 2009-06-03

Family

ID=37106941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006132110A Expired - Fee Related JP4271695B2 (ja) 2005-05-12 2006-05-11 無水結晶形態のN−[1−(2−エトキシエチル)−5−(N−エチル−N−メチルアミノ)−7−(4−メチルピリジン−2−イル−アミノ)−1H−ピラゾロ[4,3−d]ピリミジン−3−カルボニル]メタンスルホンアミド
JP2009001627A Expired - Fee Related JP4996631B2 (ja) 2005-05-12 2009-01-07 無水結晶形態のN−[1−(2−エトキシエチル)−5−(N−エチル−N−メチルアミノ)−7−(4−メチルピリジン−2−イル−アミノ)−1H−ピラゾロ[4,3−d]ピリミジン−3−カルボニル]メタンスルホンアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009001627A Expired - Fee Related JP4996631B2 (ja) 2005-05-12 2009-01-07 無水結晶形態のN−[1−(2−エトキシエチル)−5−(N−エチル−N−メチルアミノ)−7−(4−メチルピリジン−2−イル−アミノ)−1H−ピラゾロ[4,3−d]ピリミジン−3−カルボニル]メタンスルホンアミド

Country Status (23)

Country Link
US (3) US8227475B2 (https=)
EP (1) EP1881985B1 (https=)
JP (2) JP4271695B2 (https=)
KR (1) KR100939890B1 (https=)
AT (1) ATE493413T1 (https=)
AU (1) AU2006245416B2 (https=)
BR (1) BRPI0609225A2 (https=)
CA (1) CA2608018C (https=)
CR (1) CR9505A (https=)
CY (1) CY1111171T1 (https=)
DE (1) DE602006019231D1 (https=)
DK (1) DK1881985T3 (https=)
EA (1) EA012577B1 (https=)
IL (1) IL186693A (https=)
MA (1) MA29447B1 (https=)
MX (1) MX2007013215A (https=)
NO (1) NO20075258L (https=)
NZ (1) NZ564187A (https=)
PL (1) PL1881985T3 (https=)
PT (1) PT1881985E (https=)
TN (1) TNSN07414A1 (https=)
TW (1) TWI380986B (https=)
WO (1) WO2006120552A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7676953B2 (en) * 2006-12-29 2010-03-16 Signature Control Systems, Inc. Calibration and metering methods for wood kiln moisture measurement
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
MX363696B (es) 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014064566A1 (en) 2012-10-23 2014-05-01 Pfizer Inc. Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
PL3177624T3 (pl) 2014-08-06 2019-09-30 Pfizer Inc. Związki imidazopirydazynowe
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
EP3766885B1 (en) 2015-06-17 2022-05-25 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
SG11201806383TA (en) 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
WO2018002760A1 (en) 2016-07-01 2018-01-04 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
BR112019026955A2 (pt) 2017-06-22 2020-06-30 Pfizer Inc. derivados de di-hidro-pirrolo-piridina
EP4219464A1 (en) 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
HRP20000712A2 (en) 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
EP1123296B1 (en) 1998-10-23 2003-09-17 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
ES2231521T3 (es) * 2000-07-28 2005-05-16 Pfizer Inc. Agente terapeutico cristalino.
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
EA008596B1 (ru) * 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
JP2008517994A (ja) 2004-10-28 2008-05-29 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 新規医薬品

Similar Documents

Publication Publication Date Title
JP2006316058A5 (https=)
CA2608018A1 (en) Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
ES2299501T3 (es) Compuestos heterociclicos utiles como inhibidores de tirosina-quinasas.
IL210071A (en) Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JP2019501865A5 (https=)
FI2134702T4 (fi) 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
NZ601150A (en) Novel substituted bicyclic triazole derivatives as gamma secretase modulators
JP2012502067A5 (https=)
MX2007006497A (es) Nuevos derivados de pirrolo [3,2-d] pirimidin-4-ona y su uso en terapia.
JP2009537498A5 (https=)
RU2015132371A (ru) Твердые формы селективного ингибитора CDK4/6
AU2016298962B2 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
WO2006130160A3 (en) Furanopyridine derivatives as ack1 and lck modulators
WO2005077950A3 (en) Medicaments with hm74a receptor activity
RU2018101363A (ru) Кристаллическая форма свободного основания лорлатиниба
JP2012512158A5 (https=)
JP2017039702A5 (https=)
RU2022109286A (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
FI3894411T3 (fi) 7-fenoksi-n-(3-atsabisyklo[3.2.1]oktan-8-yyli)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triatsoli-2-amiinijohdannaisia ja niihin liittyviä yhdisteitä gammasekretaasin modulaattoreina alzheimerin taudin hoitoon
JP2021515015A5 (https=)
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
JP2007527913A5 (https=)
WO2004041794A8 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines